Identification of a novel germline missense mutation of the androgen receptor in African American men with familial prostate cancer

Asian Journal of Andrology

Volumn 12, Issue 3, 2010, Pages 336-343

  Hu, Si Yi ^a   Liu, Tao ^a   Liu, Zhen Zhen ^a   Ledet, Elisa ^a   Velasco Gonzalez, Cruz ^b   Mandal, Diptasri M ^a   Koochekpour, Shahriar ^a,c  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c NONE   (United States)

Author keywords

African Americans; Androgen receptor; Familial prostate cancer; Germline mutation

Indexed keywords

ANDROGEN RECEPTOR; GENOMIC DNA; PROSTATE SPECIFIC ANTIGEN;

AFRICAN AMERICAN; ARTICLE; BINDING AFFINITY; CANCER INCIDENCE; CANCER MORTALITY; CAUCASIAN; CONTROLLED STUDY; DNA BINDING; EXON; FAMILIAL CANCER; FAMILY HISTORY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENOME ANALYSIS; GENOTYPE; GERM LINE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROSTATE CANCER; RESTRICTION MAPPING;

ADENOCARCINOMA; AFRICAN AMERICANS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; LOUISIANA; MALE; MIDDLE AGED; MUTATION, MISSENSE; PEDIGREE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 77952036288     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2010.5     Document Type: Article

References (32)

1. Smith JR, Freije D, Carpten JD, Grönberg H, Xu J, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996;274:1371-4.
2. Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 1998;62:1416-24.
3. Gibbs M, Stanford JL, Mclndoe RA, Jarvik GP, Kolb S, et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 1999;64:776-87.
4. Cancel-Tassin G, Cussenot O. Genetic susceptibility to prostate cancer. BJU Int 2005;96:1380-5.
5. Uchida T, Wang C, Sato T, Gao J, Takashima R, et al. BRCA1 gene mutation and loss of heterozygosity on chromosome 17q21 in primary prostate cancer. Int J Cancer 1999;84:19-23.
6. Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, et al. Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer 1999;35:1248-57.
7. Reichardt JKV, Makridakis N, Henderson BE, Yu MC, Pike MC, et al. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res 1995;55:3973-5.
8. Feldman D. Androgen and vitamin D receptor gene polymorphisms: the long and short of prostate cancer risk. J Natl Cancer Inst 1997;89:109-11.
9. Ingles SA, Ross RK, Yu MC, Irvine RA, Pera LG, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166-70.
10. Gottlieb B, Beitel LK, Wu JH, Trifiro M. The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat 2004;23:527-33.
11. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
12. Mononen N, Syrjäkoski K, Matikainen M, Tammela TLJ, Schleutker J, et al. Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormon-binding of the androgen receptor gene. Cancer Res 2000;60:6479-81.
13. Koivisto PA, Hyytinen ER, Matikainen M, Tammela TL, Ikonen T, et al. Germline mutation analysis of the androgen receptor gene in Finnish patients with prostate cancer. J Urol 2004;171:431-3.
14. Mandal DM, Sartor O, Halton SL, Mercante DE, Bailey-Wilson JE, et al. Recruitment strategies and comparison of prostate cancer specific clinical data on African-American and Caucasian males with and without family history. Prostate Cancer Prostatic Dis 2008;11:274-9.
15. Lubahn DB, Brown TR, Simental JA, Higgs HN, Migeon CJ, et al. Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proc Natl Acad Sci USA 1989;86:9534-8.
16. Tournamille C, Colin Y, Cartron JP, Le Van Kim C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat Genet 1995;10:224-8.
17. Parra EJ, Marcini A, Akey J, Martinson J, Batzer MA, et al. Estimating African American admixture proportions by use of population-specific alleles. Am J Hum Genet 1998;63:1839-51.
18. Zeegers MP, Kiemeney LA, Nieder AM, Ostrer H. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiol Biomarkers Prev 2004;13:1765-71.
19. Bratt O, Borg A, Kristoffersson U, Lundgren R, Zhang QX, et al. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 1999;81:672-6.
20. Hardy DO, Scher HI, Bogenreider T, Sabbatini P, Zhang ZF, et al. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab 1996;81:4400-5.
21. Cramer SD, Sun J, Zheng SL, Xu J, Peehl DM. Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate. Cancer Epidemiol Biomarkers Prev 2008;17:2451-7.
22. Lai J, Kedda MA, Hinze K, Smith RLG, Yaxley J, et al. PSA/KLK3 ARE1 promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis 2007;28:1032-9.
23. Binnie MC, Alexander FE, Heald C, Habib FK. Polymorphic forms of prostate specifc antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer. Prostate 2005;63:309-15.
24. Boehnke M. Allele frequency estimation from data on relatives. Am J Hum Genet 1991;48:22-5.
25. Horvath S, Laird NM, Knapp M. The transmission/disequilibrium test and parental-genotype reconstruction for X-chromosomal markers. Am J Hum Genet 2000;66:1161-7.
26. American Cancer Society. Cancer Facts and Figures 2008 (Accessed 13 August 2008 at URL: http://www.cancer.org/docroot/STT/content/STT-1x-Cancer- Facts-and-Figures-2008.asp?from=fast).
27. Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol 2007;177:444-9.
28. Gaston KE, Kim D, Singh S, Ford OH, Mohler JL. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol 2003;170:990-3. (Pubitemid 36999618)
29. Crocitto LE, Henderson BE, Coetzee GA. Identification of two germline point mutations in the 5' UTR of the androgen receptor gene in men with prostate cancer. Cancer Res 1997;158:1599-601.
30. Evans BA, Harper ME, Daniells CE, Watts CE, Matenhelia S, et al. Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis. Prostate 1996;28:162-71.
31. Rajender S, Singh L, Thangaraj K. Phenotypic heterogeneity of mutations in androgen receptor gene. Asian J Androl 2007;9:147-79.
32. Jesser C, Mucci L, Farmer D, Moon C, Li H, et al. Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels. Br J Cancer 2008;99:1743-7.